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Abstract. The present study was undertaken to determine whether endometrial cancer 
cell line HEC-1-A differ from nontransformed cells, in that the cAMP and protein 
kinase C pathways may enhance IGF-I effects in mitogenesis by acting at the G ,  phase of 
the cell cycle instead of Go. Immunofluorescence staining of HEC-1-A cells using the 
proliferating cell nuclear antigen (PCNA) monoclonal antibody and flow cytometric 
analysis determined that HEC-1-A cells do not enter the G,, phase of the cell cycle when 
incubated in a serum-free medium. Approximately 5 1% of the cells were in G, ,  12% 
were in S and 37% in GI phase of the cell cycle prior to treatment. Forskolin and 
phorbol-12-myristate 13-acetate (PMA) were used to stimulate cAMP production and 
protein kinase C activity, respectively. IGF-I, forskolin and PMA each increased 
( P  < 0.01) [3HH]-thymidine incorporation in a dose and time dependent manner. The 
interaction of forskolin and PMA with IGF-I was then determined. Cells preincubated 
with forskolin or PMA followed by incubation with IFG-I incorporated significantly 
more (P<0.01) [3HH]-thymidine into DNA than controls or any treatment alone. It is 
concluded that forskolin and, to a lesser extent, PMA exert their effect at the G, phase of 
the cycle to enhance IGF-I effects in cell proliferation. 
Insulin-like growth factor-I (IGF-I) is known to elicit a mitogenic response in vitro and in vivo in a 
variety of normal and neoplastic cells (Sell et a/. 1993, Pietrzkowski et ul. 1992, Dickson ef a/. 
1987, Tricoli eta/ .  1986). Mitogenesis, however, is a multistep process where a competence signal 
stimulates the cells to traverse the G,,/G, phase of the cell cycle, and progression factors such as 
IGF-I then commit the cell to DNA synthesis. For example, studies performed with mouse 
embryo have shown that the EGF receptor requires the presence of  a functional IGF-I receptor 
for its mitogenic and transforming activities (Coppola et ul. 1994). In addition, studies with Balb 
C/3T3 cells, have shown that quiescent fibroblasts do  not respond mitogenically to EGF unless 
they have been pretreated with cAMP analogs (Olashaw et a/. 1988). Similarly, in FRTL-5 cells, a 
line of nontransformed rat thyroid cells, the effects of IGF-I on [ 'HI-thymidine incorporation have 
been shown to be significantly enhanced by prior exposure to cyclic AMP (Tramontano et a/. 
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1988). However, cells from primary carcinomas, as well as established cancer cell lines, differ 
from normal cells, in the sense that cancer cells arrest in the G I  phase of the cell cycle instead of 
G,, during density inhibition or serum deprivation (Tay et al. 199 1). Therefore, factors such a s  
CAMP or protein kinase C which are known to play a competence role in various cell systems. 
would n o t  act in cancer cells to recruit them from the G,, phase into the cell cycle but instead 
enhance the mitogenic activity of growth factor stimulated cells by acting at the G I  phase o f  thc 
We have been studying the growth regulation of transformed cell line HEC-I-A which is 
derivcd from endometrial adenocarcinoma (Pearl ef al. 1993). This cell line possesses type 1 ICF 
receptor (Perkonen et al. 199 1 ) and IGF-1 stimulates both [3H]-thymidine incorporation and cell 
growth as evidenced by an increase in cell number (Talavera et ul. 1992). Furthcrrnore, trcatment 
o f  this cell line with PMA and forskolin also stimulates mitogenesis, suggesting that protein kinasc 
C and cyclic AMP mediated cellular mechanisms might trigger the growth of  these transformed 
cells (Talavera el ul. 1992). The purpose of the present study was to examine whether protein 
kinase C and cyclic AMP would act at the G ,  phase of the cell cycle to further enhance IGF-l 
effects i n  the mitogenic activity of endometrial adenocarcinoma cell line HEC-1 -A. 
cell cycle. 
MATERlALS A N D  M E T H O D S  
Recombinant IGF-l was a generous gift from Eli Lilly Research Laboratories (Indianapolis, IN, 
USA). Fatty acid free bovine serum albumin (BSA), fetal bovine serum (FBS), phorbol 12- 
niyristate 1 3-acetate (PMA), forskolin, 8-bromo CAMP, and 1 oleoyl-2-acetyl glycerol (OAG) 
were obtained from Sigma Chemical (St Louis, MO, USA). H-stain (Hoechst, 33258 dye) was 
purchased from Aldrich (Milwaukee, WI, USA). Electrophoresis reagents and trypsin/EDTA 
solution containing 0.25% trypsin and 0.02% EDTA, were obtained from BioRad (Richmond, 
CA, USA). 
Cell cultures 
Human endometrial cancer cell line HEC- I-A (ATCC # HTB-112 batch # F-6720) was 
purchased from the American Type Culturc Collection. The cells were maintained in DME/F 12 
mixture (Sigma D2906) supplemented with 10'% fetal bovine serum, 50 pg/ml gentamycin, and 
2 U/ml nystatin. The cells were cultured in 75 cm? tissue culture flasks (Corning Glass Works. 
Corning, NY, USA) and maintained at 37°C in a water saturated air with 5% CO?. For 
subculturing, the medium was removed and replaced with fresh buffer containing 0.25'%, trypsin 
and 0.02'%, EDTA solution. After 2 min, the solution was removed and the flasks maintained ;it 
37°C for approximately I 0  niin to allow the cells to detach. The cclls were suspended in fresh 
medium and centrifuged at 1 S O  x g for 10 min. The supernatant was discarded, and the cell pellet 
resuspended in fresh medium. The resuspended cells were cultured in 24 well plates and incubated 
in serum-free DME medium (0.3% BSA) for 24 h to allow for cell attachment. Following this 
incubation, the cells were trcated immcdiately as described in the figures. Given the aggressive 
growth of these cells in serum-free medium. possibly due to autocrine growth factors being 
secreted by the cells, initial results were often inconsistent regarding the magnitude of their 
response to growth promoting agents. However, we have found that a consistent response to 
growth factor stimulation is observed when the cells arc washed extensively (three times) with 
serum-free medium prior to treatment and when the cclls are treated 24 h following their initial 
plating in the absence of serum. These conditions were used for all incubations in o u r  studies. 
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Immunofluorescence staining of HEC- 1 -A cells 
The endometrial HEC- 1-A cells were removed from the wells with fresh buffer containing 0.25% 
trypsin and 0.02% EDTA solution, as described above, for subculturing and washed in PBS. The 
cell pellet was resuspended in 500 pl o f  a solution containing 1% paraformaldehyde, vortexed 
and incubated for 20min. Following a wash with PBS, the cells were then mounted on a 
microslide for fluorescent microscopic observation (Menge et ul. 1993). The fixed cells were 
incubated with 200 pl containing 20 pg/ml of mouse proliferating cell nuclear monoclonal 
antibody (PCNA IgG,,,: Oncogene Science, Uniondale, NY, USA). Negative controls were 
incubated in the presence of mouse IgGzil. The cells were then washed with 2ml of PBS and 
incubated with 200 p1 of a second antibody (anti IgG,,) labelled with fluorescein isothiocyanate 
(FITC: Dako, Carpinteria. CA, USA). Slides were examined using a Fluorescence microscope 
(Carl Zeiss, Germany). 
To analyse for the presence of the cell cycle dependent protein Ki-67, the 
immunofluorescence analysis was carried out as described by Coltrera and Cown ( 199 1 ). In brief, 
the cells were fixed using absolute methanol for 30min. The fixed cells were incubated with 
200 pl of mouse Ki-67 antibody (Dako Corporation, Santa Barbara, CA, USA) at 1 : 25 dilution. 
The cells were then washed with 2 ml of PBS and incubated with 200 pl of Fluorescin-conjugated 
(FITC; 1 : 100) goat anti-mouse anti-lgG (Fc specific), purchased from Sigma Chemical (St. Louis, 
MO, USA). The antibodies were diluted with PBS containing 1°L1 BSA. 
Flow cytometry and cell cycle analysis 
Cells were plated at a density of 50 000 cells/well in DME, incubated with bromodeoxyuridine 
(BrdUrd; 10 PM) for 30 min prior to harvesting and processed for indirect immunofluorescence 
staining as described by the manufacturer (Beckton Dickinson lmmunocytometry Systems, San 
Jose, CA, USA). Processed cells were analysed using an Elite Flowcytometer (Coulter 
Corporation, Hialeah, FL, USA) fitted with an Argon Ion Laser adjusted to emit 15 mW at 
488 nm. Green fluorescence was measured through a BP525 nm filter. Propidium iodide red 
fluorescence yielded cell cycle distributions unaffected by BrdUrd incorporation and was 
measured through a BP630 nm filter. The bivariate fluorescent distributions were displayed in 
dot blots (64 x 64 channel array). Each analysis was carried out on at least 10  000 events and an 
analysis region was placed on the dual parameter histogram of the isotype control, so that 5% of 
the cells in the control sample were located in the region. Any sample giving a signal of greater 
than 5% above the control was considered positive. Compartmentalization of the cell cycle was 
analysed on an Epics Elite Workstation (Coulter Corporation). 
Thymidine incorporation assay 
Thymidine incorporation studies were performed in 24 well plates (Imai el al. 1982). Cells were 
plated at a density of 50000 cells/well in DME and treated for 24 h intervals, unless specified 
otherwise. Four hours prior to completion, 1 pCi [-'H]-thymidine was added to each well. Cells 
were then washed with ice cold PBS and incubated with TCA (5 "h)  to remove the acid soluble 
['HI-thymidine pool. Cells werc washed again with PBS and dissolved in 500 pl NaOH (0.2 M )  to 
recover the remaining incorporated ['HI-thymidine. This was transferred t o  scintillation vials 
containing 10 ml Biosafe 11. After neutralization with 0.2 N HCI, the radioactivity was determined 
using a beta particle counter. 
Cell growth assay 
HEC- 1 -A cells (50 000 cells/well) were plated in quadruplicate in 24 well plates containing 
500 pl phenol red-free DME/F 12 medium containing 0.3"/0 BSA in the absence or presence of 
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various treatments. Following the incubations, the cells were harvested with 500 pI trypsin/EDTA 
solution, as described for cell cultures. The trypsin was neutralized with 500 pI fresh medium. 
The cell number was quantitated in four aliquots from each replicate using a hemocytomcter. 
IGF-I binding assay 
IGF-1 iodination and binding assays were carried out as described previously (Talavera ct al. 
1990) with slight modifications. Briefly, cells were incubated with treatments as described in the 
figures. At the end of the treatment period, cells were washed and incubated with medium 
containing '2sI-IGF-I in the absence or presence of a 200-fold excess of unlabelled ligand. 
Incubations were performed at 4°C for 16 h. Unbound growth factor was removed with ice-cold 
growth medium wash. Cells were then lysed with 0.5 N sodium hydroxide and incubated at 37°C 
for 30 min. The radioactivity was quantitated in a gamma counter. Specific binding was 
determined by subtracting the nonspecific binding from total binding. 
DNAassay 
HEC-1-A cells were cultured as described for the growth assay. DNA was analysed by the 
procedure of Labarca & Paigen (1982). The cells were solubilized with 0.25 ml of 0.5 N sodium 
hydroxide and incubated at 37°C for 1 h. High-salt DNA assay buffer (0.75 ml, 0.5 M sodium 
phosphate, 2 M sodium chloride, pH 7.4) and bisbenzimidazole (32 pg/ml) were added and the pH 
adjusted to 7.2-7.4 with 0.5 N hydrochloric acid. DNA standard5 were prepared using calf thymus 
DNA. Fluorescence was measured at wavelengths set at 356 nM (excitation) and 458 n M  
(emission). 
Statistical analysis 
The data represent the mean +SEM of the number of determination analysed by ANOVA and a 
Student's I-test to compare differences among treatment groups. Each experiment was repeated 
at least four times. 
RESULTS 
Expression of PCNA on HEC-I-A cells and flow cytometric analysis 
Initial studies were performed to determine the percentage of cells that were not in the GI, phase 
of the cell cycle through immunohistochemical studies using the monoclonal antibody to PCNA. 
This antibody is not taken up by cells that are either in GI, or M phase of the cell cycle. Figure 1 
shows the cells observed under fluorescent light. The percentage of cells staining positive f o r  
PCNA was 100%, suggesting that the cells were not in G,, phase of the cell cycle when trcated. 
Negative controls that were incubated in the presence of mouse IgGza did not stain (data not 
shown). Some cells exhibited more fluorescent light than others which is consistent with cells that 
are found at different phases of the cell cycle. 
To further confirm our observations that these cells do not exit to the G,, phase when 
incubated in the absence of serum, the cells were analysed for the presence of Ki-67 protein 
which is known to be expressed throughout the cell cycle but not in the GI, phase. In order to 
examine this, the cells were either plated at a density of 50000 ml- ' (low density), or grown to a 
density arrested state (high density) and incubated in the absence of serum (0.3% BSA) for 24 h 
prior to the analysis. Figure 2a shows the staining of cells plated at low density. Figure 2b shows 
the staining of cells that were density arrested prior to the analysis. Some cells exhibited more 
fluorescence than others. However, the percentage of cells staining positive for Ki-67 was 10C1"/,, 
for both low and high density plating suggesting that HEC-I-A cells do not exit to GI, when they 
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Figure 1. PCNA expression in HEC-I -A cells as identified by indirect immunofluorescence. Cells were 
grown to contluency and subcultured into 24 well plates for 24 h in the absence of serum. Following this 




Figure 2. Ki-67 expression in HEC-I-A cells as identified by indirect immunofluorescence. a Cells were 
plated at 50000/ml and incubated in the absence of serum for 24h.  b Cells were density arrested and 
incubated in the absence of serum for 24 h. Following this incubations, the cells wcre harvested and analysed 
through immunostaining as described in the Materials and Methods section. 
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are incubated in the absence of serum and density arrested. As expected, control5 that wcrc 
incubated with mouse IgC,, alone did not exhibit tluorescence (data not shown). 
When nuclei from HEC-1-A cells were analysed for cell cycle phase distributions based on 
DNA content using flow cytometry, the results show that approximately 51% of the cells were in 
the G ,  phase of  the cycle (Table I ) .  These results demonstrate that HEC-1-A cells continue t o  
grow and do not enter the G,, phase of the cell cycle when incubated in the absence of serum. 
Effect of IGF-I, forskolin and PMA on (3H]-thymidine incorporation 
Initial studies were performed to examine the time course of IGF-1 effect on [’HI-thymidine 
incorporation in the endometrial adenocarcinoma cell line HEC-1-A. The cell exhibited a 32% 
increase (1’ < 0.05) in thymidine incorporation during the first 12 h of incubation and a maximum 
increase (P<O.OI)  was observed at 24 h (data not shown). A 50% increase (1’<0.01) in /’HI- 
thymidine incorporation was observed with 100 ng/ml of IGF-I (Table 2). 
The effects of forskolin and the tumour promoting phorbol ester, PMA, on [ ’HJ-thymidine 
incorporation were also tested. Our initial studies showed that a minimum of 12 and 24 h 
incubation were required for forskolin and PMA, respectively, to stimulate [ 3H]-thymidinc 
incorporation significantly (/’< 0.01). A maximum increase was observed at 24 h in response to 
both compounds (data not shown). The optimum increase (1’ < 0.0 1 ) was observed with I 0  ~ I M  
forskolin and 10 nM PMA (I’ < 0.0 1; Table 2). 
Effect of forskolin and PMA priming on IGF-I stimulation of [3H]-thymidine incorporation 
Experiments were performed to determine the effect of preincubation of HEC- 1-A cells with 
forskolin and PMA on IGF-I stimulation of I%]-thymidine incorporation into DNA. In thew 
studies, the cells were cultured for 24 h with or  without IGF-1 (1  00 ng/ml), forskolin ( 1 0  p ~ )  o r  
PMA (10 n M ) .  The cells were then washed three times with fresh serum-free medium (0.3% BSA) 
and were cultured f o r  20 h in the absence or presence of a second mitogcnic agent as described in 
Figure 3 and Figure 4. j7H]-Thymidine was then added in DME medium and its incorporation 
into DNA was measured 4 h  later. The response to the treatment was similar rcgardlcsc of 
Table 1. Distribution of serum deprived HEC-1-A cells 
in the G I ,  S and GJM phase of the cell cycle 
~~ 






5 1  
12 
37 
HEC- 1 -A cells were grown to confluency and 
subcultured into 24 well plates (SO 000 cells/well). The 
cells were then incubated in the absence (0.3”/0 BSA) or 
presence of 10% FBS (exponential growth) and the 
distribution of cells in the cell cycle analysed through 
tlow cytometry as described in the Materials and 
Methods section. These results are representative of six 
individual analyses with similar results. 
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whether the cells were incubated with a treatment once for 24 h or incubated for two consecutive 
24 h treatment periods (data not shown). 
Pretreatment with forskolin (Figure 3) or PMA (Figure 4)  for 24 h increased IGF-I stimulation 
of [3H]-thymidine incorporation over controls or treatment with a single agent alone. The increase 
of IGF-1 effects by PMA was marginal when compared to that produced by forskolin (Figures 3 
and 4). 
Time course of forskolin and PMA priming on IGF-I stimulated I3Hj-thymidine incorporation 
Cells primed for 3 h (or more) with forskolin exhibited a significant (P<O.Ol) increase in [-'HI- 
thymidine incorporation in response to IGF-I treatment compared to control or either treatment 
alone (Table 3). However, when cells were primed with PMA for less than 24 h, [-'H]-thymidine 
incorporation seen was comparable to that of IGF-I alone. Therefore, a minimum priming period 
of 24 h with PMA was required to enhance IGF-I stimulated [3H]-thymidine incorporation above 
( P  < 0.01) that seen with either treatment alone (Table 3). The increased responsiveness to IGF-I, 
apparently due to an increase in the number of IGF-I receptors, was then examined. Cells that 
were preincubated with either treatment for less than 12 h did not exhibit an increase in the 
number of IGF-I receptors. However, the number of receptors increased ( P  < 0.01) in response to 
12 h incubation with forskolin over control with binding capacities of 3.7 and 6.9 n M  for control 
and forskolin, respectively (Figure 5a). Similarly, treatment with PMA induced a significant 
Table 2. Dose effect of IGF-I, forskolin and PMA on 
[jHI-thymidine incorporation by HEC-1 -A cells 
Thymidine incorporation 
into DNA 
Treatment Dose dpm/well 
IGF-1 (ng/ml) 0 1741 k 3 6  
0.1 1 7 8 8 f  160 
1 1851 *I80 
I 0 2508 f 160% 
100 2689 f 190% 
Forskolin ( PM) 0 1553 +89  
0.0 1 I531 f 9 5  
0.1 1683f I94 
1 2709 f 125* 
10 4323 f 188* 
100 3304 rt 127* 
PMA (nM) 0 1 6 0 9 f 7 6  
0.1 I614 rt 82 
1 2415f94* 
10 2420 k I03* 
I00 22882~171" 
HEC-I -A cells were incubated with the indicated concentra- 
tions of IGF-I, forskolin or PMA for 24 h. During the last 4 h of 
the incubation, the cells were also exposed to [ 'HI-thymidine. 
The incorporation of [jH]-thymidine was measured as described 
in the Materials and Methods section. Data shown are the mean 
f SEM per well in replicates of four. *I' < 0.01 w. control. 
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Figure 3. Effect of forskolin pre-incubation of HEC-1-A cells in IGF-I stimulation of ['HI-thymidine 
incorporation. The cells were preincubated in the absence or presence of either IGF-I (100 ng/ml) or 
forskolin ( 1 0 , ~ ~ )  for 24 h. At the end of this incubation, the cells were washed three times and incubated for 
an additional 24 h with the treatments indicated at the bottom of each bar. ['HHI-Thymidine incorporation was 
measured during the last 4 h of the 24 h period as described in the Materials and Methods section. The 
results shown are the mean ~ S E M  for well in replicates of six. The I' values denote significant differences 
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Control(24h) IGF-I(24h) PMA(24h) PMA(24 h )  
Control (24 h) IGF-I (24 h) PMA(24 h) IGF-I (24 h) 
Figure 4. Effect of preincubation of HEC-1-A cells with PMA on the subsequent response of [3H]-thymidine 
incorporation to IGF-I. The cells were preincubated in the absence or presence of either IGF-I ( 100 ng/ml) or 
PMA ( 10 ng/ml) or PMA (10 n M )  for 24 h. At the end of this incubation, the cells were washed three times 
and incubated for an additional 24 h in the presence of the treatments indicated at the bottom of each bar. 
]'HI-Thymidine incorporation was measured as for Figure 3. The P values denote significant differences 
when compared to controls. 
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Table 3. Effect of forskolin and PMA priming on IGF-I time course of DNA synthesis in HEC-1-A cells 
Incubation Thymidine Incorporation into DNA (dpm/well) 
First Second 3 h  6 h  1 2 h  24h 
Control Control 1615k 129 1374f  139 1530 f 67 1477 f 286 
Forskolin Forskolin 3130f  113* 3229 f 138* 3427 f 160* 3631 f 358* 
IGF IGF-1 2053 f 93* 2241 f 125* 2580 f 178* 2710f  192* 
Forskolin IGF-I 4725 f 149* 4836 f 123* 5523k 187* 6028 f 117* 
Control Control 1509 f 86 1474 f 148 1 4 9 5 f 8 2  1518f  124 
PMA PMA 2140f 142* 2160+ 172* 2322 f 152* 2391 k 76* 
IGF-I IGF-I 2757 f 116* 2830 f 140* 2874 f 116* 2964f  101* 
PMA IGF-I 2094 f 156* 2241 f 196* 2473 f 128* 3672 f 124* 
HEC-1-A cells were first preincubated in the presence of either IGF-I ( I00 ng/ml) forskolin ( 10 PM), or 
PMA (10 n M )  as indicated at the left of each row for 3,6,  12 and 24 h as indicated at the top of each column. 
At the end of this incubation, the cells were treated for a second 20 h period in the presence of the agents 
indicated at the left of each row and exposed for an additional 4 h to ['HI-thymidine. The incorporation of 
['HI-thymidine was measured as described in the Materials and Methods section. Data shown are the mean 
f SEM per well in replicates of four. * P  < 0.01 v. untreated control. 
( P  <0.01) increase in the number of receptors with binding capacities of 3.4 and 4.8 nM for 
control and PMA, respectively (Figure 5b). The Kd, however, remained unchanged (1.77 nM) .  
Since PMA did not potentiate IGF-1 effects until after 12 h of incubation, these results suggest that 
PMA enhances IGF-I response by increasing IGF-I receptors. In contrast, the effects of forskolin 
priming appear independent of a change in IGF-I receptor number. 
Effect of IGF-I priming on forskolin and PMA stimulated ["]-thymidine incorporation 
Since IGF-I is considered to be a progression factor and not a competence factor, experiments 
were performed to evaluate the effect of IGF-I priming on the mitogenic effects of forskolin 
(Figure 6a) and PMA (Figure 6b). To accomplish this objective, HEC-1-A cells were 
preincubated for 24 h with IGF-I (100 ng/ml). At the end of the pretreatment, the cells were 
washed twice and incubated for another 24 h in the absence or presence of either forskolin 
(10 p ~ ;  Figure 6a) or PMA (10 nM; Figure 6b). The results show that the stimulatory effect of 
forskolin and PMA on ['HI-thymidine incorporation was abolished by IGF-I priming (Figure 6). 
Effect of 8-bromo-CAMP on [3H]-thymidine incorporation 
The specificity of forskolin in enhancing IGF-I effects was then evaluated. Since forskolin acts by 
increasing intracellular levels of CAMP, the effect of pretreatment with 8-bromo-CAMP in 
enhancing the effect of IGF-I on ['HI-thymidine incorporation was examined. When the cells were 
treated with 8-bromo-CAMP alone, [3H]-thymidine incorporation by the HEC- 1 -A cells was 
increased significantly ( P  < 0.01). Pretreatment with 8-bromo-CAMP enhanced ( P  < 0.01) the 
effects of IGF-I on ['HI-thymidine incorporation to levels above those observed with control or 
either treatment alone (Figure 7). 
Effect of 4a PDD and OAG on I3Hj-thymidine incorporation 
Since PMA has been reported to activate protein kinase C in several tissues and since 
diacylglycerols are known to be an intracellular activator of this enzyme, the specificity of PMA in 
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Figure 5. Comparison of IGF-I binding activity between a Control (.)and Forskolin ( 0 )  ( 1 0 ~ ~ )  and b
Control (.)and PMA ( 0 )  ( 1 O n ~ )  treated HEC-1-A cells. The specific activity of '2sI-IGF-I was adjusted to 
25000 cpm/ng protein by the addition of unlabelled IGF-I. The cells were preincubated in the absence or 
presence of either Forskolin ( 1 0 ~ ~ )  or PMA (10 nM) for 12 h. At the end of this incubation, the cells were 
incubated with various concentrations of 12sI-IGF-I (1-100 ng/ml) for 16 h at 4°C. To determine nonspecific 
binding, incubations were performed in the presence or absence of unlabelled IGF-I (200 ng/ml). The data 
were transformed into Scatchard plots. The values in the ordinate represent percent of bound over free. 
enhancing the effects of IGF-I on [3H]-thymidine incorporation was determined. The cells were 
pretreated with diacylglycerol, OAG, and the non-tumour promoting phorbol ester 4a PDD. 
When the cells were treated with 4a  PDD alone (10 nM),  there was no increase in [3H]-thymidine 
incorporation (Figure 8). When cells were pretreated with 4a PDD followed by IGF-I, +ere was 
no increase in [3H]-thymidine incorporation over that produced by IGF-I alone (Figure 8). OAG 
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(24 h )  (24h) (24h) (24 h )  (24 h )  
(24h)  (24 h )  (24 h) (24h)  (24h) 
Control Control IGF-I Forskolin Forskolin 
P <  0.01 
Control IGF-I IGF-I PMA IGF-I 
(24h)  (24 h )  ( 2 4 h ) -  (24 h) 
Control Control IGF-1 PMA PMA 
(24 h) (24h)  (24 h) (24 h) (24 h )  
Figure 6. Effect of preincubation of HEC-1-A cells with IGF-I on a forskolin and b PMA stimulation of 
[3H]-thymidine incorporation. The cells were preincubated in the absence or presence of either IGF-I 
(100 ng/ml), forskolin ( 10 p ~ ) ,  or PMA (10 nM) for 24 h. At the end of this incubation, the cells were washed 
three times and incubated for an additional 24 h with the treatments indicated at the bottom of each bar. 
[3HH]-Thymidine incorporation was measured as described for Figure 3. The P values denote significant 
differences when compared to controls. 
(1 PM) alone increased (P < 0.01) [3H]-thymidine incorporation (Figure 8) and enhanced 
(P < 0.01) the effects of IGF-I (Figure 8). The increase in [3H]-thymidine incorporation in OAG 
pretreated cells stimulated with IGF-I was slightly higher (P < 0.05) than that produced by either 
IGF-I or OAG alone (Figure 8). 
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Figure 7. Effect of preincubation of HEC-1-A cells with 8-bromo-CAMP on the subsequent response to 
IGF-I. The cells were preincubated in the absence or presence of either IGF-I (100 ng/ml) or 8-bromo-CAMP 
(100 ,LAM) for 24 h. At the end of this incubation, the cells were washed three times and incubated for an 
additional 24 h in the presence of the treatments indicated at the bottom of each bar. ['Hi-Thymidine 
incorporation was measured as described for Figure 4. The t' values denote significant differences when 
compared to controls. 
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Figure 8. Effect of preincubation of HEC-I-A cells with 4 a  PDD and OAG on the subsequent response to 
IGF-I. The cells were preincubated in the absence or presence of either 1GF-I ( 100 nglrnl), PDD ( 10 I ~ M ) ,  or 
OAG ( I  PM) for 24 h. At the end of this incubation, the cells were washed and incubated for an additional 
24 h in the presence of the treatments indicated at the bottom of each bar. ['HI-Thymidine incorporation was 
measured as described for Figure 4. The I' values denote significant differences when compared to controls. 
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Table 4. Effect of forskolin and PMA priming on 




First Second Cell number/well 
Control Control 58493 k 3438 
IGF-I IGF-l 83 544 * 6842* 
Forskolin Forskolin 103633+5382* 
PMA PMA 74209k  4862* 
Forskolin IGF-l 143573+ 10893* 
PMA IGF-I 100206+8532* 
Effect of forskolin and PMA priming on IGF-I 
stimulated cell proliferation. The cells were incubated 
in the absence or presence of either IGF-I ( 100 ngiml), 
forskolin (10  PM), or PMA ( 1 0  n M )  for 24 h. At the end 
of this period, the cells were washed three times and 
incubated for an additional 24 h in the presence of the 
treatments indicated far left of each row. Cells were 
harvested and counted as described in the Materials 
and Methods section. The results shown are the mean 
+SEM. The numbers were rounded to the nearest 
hundred. *I’ < 0.0 1 v. untreated control. 
Forskolin and PMA priming effect on IGF-I induced cell proliferation 
The effects of forskolin and PMA on IGF-I mediated increase in i3H]-thymidine incorporation 
was further confirmed by determining the cell number. Forskolin and PMA enhanced the effects 
of IGF-I on cell proliferation ( P  < 0.0 1) above their respective treatment alone (Table 4). 
DISCUSSION 
Although the effect of CAMP or PKC on cell proliferation are not restricted to the G,,-S transition 
phase, the present study focused on this part of the cell cycle, since the purpose of the study was 
to examine the effects of forskolin and PMA priming on IGF-I stimulation of thymidine 
incorporation and cell proliferation. The results suggest that forskolin and PMA may act beyond 
the G,, phase to enhance IGF-I effects in HEC-1-A cell proliferation. These observations are 
supported by the results obtained with irnmunofluorescence staining, using the PCNA 
monoclonal antibody and flow cytornetric analysis. The proliferating cell nuclear antigen is a 
36 kDa protein that has been identified as an auxiliary protein of DNA polymerase 6 (Bravo et a/. 
1987). The enzyme activity increases through G , ,  peaks at G , /S  phase interface and decreases 
through G,, reaching virtually undetectable levels by immunocytochemical methods in M and G,, 
phase of the cell cycle (Morris & Mathews 1989). The granular staining observed in our studies 
was consistent with that reported in other cell systems (Coltrera & Gown 1991). The absence of 
immunofluorescence in our controls and its presence in cells incubated with the monoclonal anti 
PCNA antibody demonstrate that PCNA is expressed in HEC-1-A cells, and the observations are 
consistent with reports showing that cancer cells do not’enter the G,, phase of the cell cycle. These 
results were further confirmed using an antibody against Ki-67, a known cell cycle specific 
antigen. Thus in HEC-1-A cells, regulatory growth factors act predominantly in the G , / S  phase 
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and do not potentiate growth factor response by recruiting cells from their quiescent state. It is 
also conceivable that competence factors act at the G2/M transition phase of the cell cycle. 
The absence of unstained cells also implies that none of the cells were in the M phase of the 
cell cycle. Alternatively, PCNA staining may not be the best approach to identify cells that are in 
the M phase. However, the immunofluorescence staining was performed only 24 h following the 
initial plating. The doubling time for HEC- 1-A cells is approximately 52 h (Kuramoto et ul. 1972). 
In the present study, following 48 h incubation, the number of untreated cells increased only 16% 
from their initial plating density of approximately 50000 cells (Table 4), suggesting that serum 
deprivation decreases their growth rate significantly. Thus, the possibility that none of the cells 
were in the M phase, when the cells were harvested for the PCNA analysis, cannot be ruled out. 
Further studies will examine this possibility. 
The finding that a higher percentage of cells exist in the GJM phase of the cycle compared to 
the S phase (Table 1) may suggest that the factors that act at the GJM transition phase to 
stimulate mitosis are absent and the transition of the cells slows down when plated in a serum-free 
media. Alternatively, the apparent increase of cells present in the GJM transition phase could 
reflect cell doublets from the G I  phase of the cycle contaminating the GJM peak analysed by the 
flow cytometer. Further studies are needed in order to examine this possibility. 
Each treatment alone was able to increase cell replication of endometrial adenocarcinoma cell 
line HEC- 1-A. Moreover, forskolin, and to a lesser extent, PMA enhanced the mitogenic response 
of the HEC-1-A cell line to IGF-I. The cAMP dependent pathway was responsible for increasing 
the mitogenic response of the forskolin primed cells to IGF-I, as the effect of forskolin was 
reproduced by the direct addition of 8-bromo-cyclic AMP. The mitogenic effect produced by 
PMA was also mimicked by exposing the cells to the diacylglycerol analog OAG, a known 
activator of protein kinase C, but not by its inactive analog, 4a PDD. This suggests that protein 
kinase C mediates the effects of PMA in the mitogenic response of the cells to IGF-I. Although 
PMA seems to mediate this effect by increasing the number of IGF-I receptors, forskolin may 
exert its effects by regulating intracellular post-receptor events. I t  is reasonable, therefore, to 
suggest that the effects of CAMP, and possibly protein kinase C dependent pathways, regulate 
early events of the cell cycle in transformed endometrial HEC- 1 -A cells. The results suggest that 
the CAMP, and possibly the protein kinase C pathway, may enhance or increase the expression of 
genes present during the G I  phase for the synthesis of enzymes involved in DNA synthesis during 
the S phase. Conversely, IGF-1 may exert its function either at the G I  /S boundary or early during 
the onset of DNA synthesis. In this context, Rozengurt (1982) has shown that cyclic AMP 
analogues act in early G I  phase of the cell cycle to potentiate the effects of insulin in quiescent 
Swiss 3T3 cells. It has also been shown that early events of the S phase in CHO cells are mediated 
by other exogenous factors (Dijkwel & Hamlin 1992). Our results support the observations of Tay 
et ul. (1991) that in cancer cells the GI phase of the cell cycle represents a point of slow growth or 
a restriction point that can be overcome by growth promoting agents. Thus, although numerous 
studies have shown that competence factors such as cAMP or  protein kinase C act in 
nontransformed cells to recruit them from the Go phase into the cell cycle, our study is the first 
one to show that in cancer cells these competence factors may act at the G I  phase of the cycle to 
enhance their response to progression factors such as IGF-I. 
The stimulatory effect of cAMP on [3H]-thymidine incorporation was much greater than that 
produced by protein kinase C stimulating agents. Similar effects have been reported for FRTL-5 
cells, which respond highly to forskolin but little to tetradecanoyl phorbol 12-myristy1, 13-acetate 
(Colleta et ul. 1987). These results suggest that, compared to the protein kinase C pathway, the 
cAMP pathway could play a more prominent role in DNA synthesis of some endocrine cells. 
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The stimulatory effect of forskolin and PMA on ['HI-thymidine incorporation was abolished 
when the cells were preincubated with IGF-I alone, which is consistent with similar effects 
reported for FRTL-5 cells (Takahashi et af .  1990). These results suggest that, in addition to acting 
as a progression factor, IGF-I may inhibit the effect of the cAMP and protein kinase C dependent 
pathway on DNA synthesis depending on the sequence of events. 
Although the mechanisms by which the mitogenic effects of IGF-I are enhanced by forskolin 
and PMA are not well understood, recent evidence suggests that the cAMP dependent pathway 
interacts with the IGF-I receptor to increase tyrosine phosphorylation (Aaronson 1991, Sibley et 
al. 1988, Ullrich & Schlessinger 1990). Studies on insulin receptors in endothelial cells have also 
shown that protein kinase C increases phosphorylation of the insulin receptor (Hachiya et al. 
1987). Other possibilities include changes in the structure and organization of cytoskeletal 
proteins and alterations in gene expression (Houslay 1991, Schimke 1984). In addition, recent 
studies have suggested that short pulses of growth factors can increase the response of cells to 
IGF-I stimulation by either increasing the number of IGF-I receptors or by providing a new 
substrate for the activated receptor (Youshinouchi & Baserga 1993). 
Our results suggest that cAMP may play a prominent role in the proliferation of HEC-1-A 
cells. Thus, CAMP, and to a lesser extent, protein kinase C responsive events, may mediate the 
biological actions responsible for enhancing the effect of IGF-I in the proliferation of transformed 
endometrial tumour cells by acting at the G ,  phase of the cell cycle. We conclude that multiple 
mitogenic pathways converge to potentiate the proliferation of endometrial adenocarcinoma cells. 
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